ClinicalTrials.gg
RecruitingNCT07934862MOVE4TWOUpdated Nov 13, 2026

Strength Training During Pregnancy: The Trial MOVE4TWO

An interventional study of Exercise in Pregnant Women, sponsored by European University Miguel de Cervantes. Recruiting at 1 site in Spain. Open to female participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by European University Miguel de Cervantes · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Study summary

Pregnancy involves substantial physiological and psychological adaptations that may affect maternal health, physical function, and quality of life. Regular physical activity during pregnancy has been associated with improvements in physical and psychological well-being and a reduced risk of certain pregnancy-related complications. Although aerobic exercise is widely recommended, the specific effects of structured strength training on maternal functional capacity, neuromuscular performance, cardiovascular function, and fetal health remain insufficiently understood.

The aim of this randomized controlled trial is to evaluate the effects of a supervised strength training program during pregnancy on maternal health-related quality of life, physical fitness, body composition, physiological biomarkers, fetal growth, and perinatal outcomes in healthy pregnant women.

Read the detailed description

Regular physical activity during pregnancy is associated with improvements in maternal physical and psychological health. Strength training may provide additional benefits for neuromuscular performance, functional capacity, body composition, and health-related quality of life. However, further randomized controlled trials are needed to determine the specific effects of supervised strength training on maternal and fetal health throughout pregnancy and the postpartum period.

This prospective, two-arm, parallel-group randomized controlled trial will be conducted in Valladolid, Spain. A total of 40 healthy primigravid women with singleton pregnancies will be recruited through prenatal care appointments. Participants will undergo baseline assessments between gestational weeks 10 and 12, followed by randomization in a 1:1 ratio to an intervention group or a control group.

Participants in the intervention group will complete three supervised strength training sessions per week, beginning in the week following baseline assessment and continuing until delivery. Training sessions will be conducted at the Universidad Europea Miguel de Cervantes under the supervision of qualified exercise professionals. Exercise intensity will be individualized using repetitions in reserve (RIR), progressing from 4-6 RIR during the first three weeks to 2-3 RIR thereafter. No sets will be performed to muscular failure.

Participants in the control group will receive general recommendations regarding physical activity and health during pregnancy and will continue their usual care.

Maternal health-related quality of life, physical activity, body composition, neuromuscular performance, functional capacity, postural control, heart rate variability, and blood biomarkers will be assessed at gestational weeks 10-12, 26-28, and 34-36, and during postpartum follow-up at weeks 8-12, as applicable. Fetal growth parameters will be assessed by obstetric ultrasound, and relevant delivery and neonatal outcomes will be recorded.

The study aims to determine whether supervised strength training during pregnancy improves maternal health and physical function and influences fetal growth and perinatal outcomes compared with usual care.

02

Conditions studied

  • Pregnant Women

Keywords

  • Gestation
  • maternal-fetal health
  • strength training
  • functional capacity
  • primigravid women
03

In context

Lead sponsor

European University Miguel de Cervantes is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primigravid women with a singleton pregnancy.
  • Age between 20 and 35 years.
  • Pre-pregnancy (BMI) below 30 kg/m².
  • Medical clearance to participate in supervised exercise.
  • Absence of pregnancy-related conditions, including gestational diabetes, preeclampsia, or gestational hypertension.
  • Availability to attend three supervised training sessions per week (approximately 60 minutes per session).

Exclusion criteria

Exclusion Criteria:

  • Musculoskeletal injury within six months before the baseline assessment.
  • Major surgery within the previous three months.
  • Any absolute or relative to exercise identified using the PARmed-X for Pregnancy questionnaire, including relevant obstetric, cardiovascular, respiratory, or systemic conditions.
  • Any other medical condition that contraindicates participation in supervised physical activity.
  • High-risk pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Control

    Participants assigned to the control group will continue their usual prenatal care and receive general recommendations regarding physical activity and healthy lifestyle behaviors during pregnancy, in accordance with current guidelines. No supervised strength training intervention will be provided as part of the study.

  • Experimental
    Exercise

    Participants assigned to the intervention group will perform three supervised strength training sessions per week, beginning after baseline assessment and continuing until delivery. Sessions will be conducted in small groups of up to six participants and supervised by qualified exercise professionals. Training intensity will be individually prescribed using repetitions in reserve (RIR), progressing from 4-6 RIR during the first three weeks to 2-3 RIR thereafter.

    Other: Exercise

Interventions

  • OtherExercise

    The intervention will consist of three supervised strength training sessions per week, conducted in person at the Universidad Europea Miguel de Cervantes. Each session will include two exercise circuits targeting major muscle groups through anterior-chain, posterior-chain, pulling, pushing, and core exercises. Exercise intensity will be individualized using repetitions in reserve (RIR), progressing from 4-6 RIR during the first three weeks to 2-3 RIR thereafter. Training loads will be adjusted according to individual performance and tolerance. Sessions will be supervised by qualified professionals, and exercises will be adapted to the participants' gestational stage and physical condition. The intervention will continue until delivery.

06

What researchers measure

Primary outcomes

  1. Change in Health-Related Quality of Life: SF-36 Physical Component Summary (PCS)

    The physical component of health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The Physical Component Summary (PCS) score will be calculated using the standardized SF-36 scoring algorithm, combining information from the eight health domains through norm-based weighting. PCS scores will be expressed as norm-based T-scores, with a reference population mean of 50 and a standard deviation of 10. Higher scores indicate better physical health-related quality of life. Changes in PCS scores will be compared between the intervention and control groups across the assessment periods.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  2. Change in Health-Related Quality of Life: SF-36 Mental Component Summary (MCS)

    The mental component of health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The Mental Component Summary (MCS) score will be calculated using the standardized SF-36 scoring algorithm, combining information from the eight health domains through norm-based weighting. MCS scores will be expressed as norm-based T-scores, with a reference population mean of 50 and a standard deviation of 10. Higher scores indicate better mental health-related quality of life. Changes in MCS scores will be compared between the intervention and control groups across the assessment periods.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

Secondary outcomes

  1. Self-Reported Physical Activity Levels

    Physical activity will be assessed using the Pregnancy Physical Activity Questionnaire-Long Form (PPAQ-LF). Physical activity energy expenditure will be expressed in metabolic equivalent hours per week (MET-hours/week), with higher values indicating greater physical activity levels.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  2. Accelerometer-Measured Moderate-to-Vigorous Physical Activity

    Moderate-to-vigorous physical activity (MVPA) will be objectively assessed using GT3X+ accelerometers (firmware v1.9.2), initialized at 30 Hz with the normal filter. Participants will wear the device on the right hip, secured by an elastic belt, for seven consecutive days at each assessment. MVPA will be expressed as total minutes per week (min/week), with higher values indicating greater physical activity levels.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  3. Weight

    Body weight will be measured using a calibrated digital scale, with participants wearing light clothing and no shoes. Measurements will be expressed in kilograms (kg). Changes in body weight will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  4. Height

    Standing height will be measured using a stadiometer and expressed in centimeters (cm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  5. Body mass index

    Body mass index (BMI) will be calculated by dividing body weight in kilograms by the square of height in meters (kg/m²). Changes in BMI will be assessed throughout pregnancy and during postpartum follow-up.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  6. Body composition (Triceps Skinfold Thickness)

    Triceps skinfold thickness will be measured on the posterior aspect of the right upper arm, at the midpoint between the acromion and olecranon, using a skinfold caliper. Three measurements will be obtained following standardized anthropometric procedures, allowing tissue recovery between measurements. The mean value will be expressed in millimeters (mm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  7. Body composition (Biceps Skinfold Thickness)

    Biceps skinfold thickness will be measured on the anterior aspect of the right upper arm, at the midpoint between the acromion and olecranon, using a skinfold caliper. Three measurements will be obtained following standardized anthropometric procedures, allowing tissue recovery between measurements. The mean value will be expressed in millimeters (mm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  8. Body composition (Subscapular Skinfold Thickness)

    Subscapular skinfold thickness will be measured immediately below the inferior angle of the right scapula, using a skinfold caliper. Three measurements will be obtained following standardized anthropometric procedures, allowing tissue recovery between measurements. The mean value will be expressed in millimeters (mm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  9. Body composition (Mid-Thigh Skinfold Thickness)

    Mid-thigh skinfold thickness will be measured on the anterior aspect of the right thigh, at the midpoint between the inguinal crease and the proximal border of the patella, using a skinfold caliper. Three measurements will be obtained following standardized anthropometric procedures, allowing tissue recovery between measurements. The mean value will be expressed in millimeters (mm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  10. Body composition (Medial Calf Skinfold Thickness)

    Medial calf skinfold thickness will be measured on the medial aspect of the right calf, at the level of its maximum circumference, using a skinfold caliper. Three measurements will be obtained following standardized anthropometric procedures, allowing tissue recovery between measurements. The mean value will be expressed in millimeters (mm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  11. Body composition (Mid-Arm Circumference)

    Mid-arm circumference will be measured on the right arm at the midpoint between the acromion and olecranon, using a non-elastic anthropometric tape. Participants will stand upright with their arms relaxed alongside the body. Three measurements will be obtained without compressing the underlying tissues, and the mean value will be expressed in centimeters (cm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  12. Body composition (Calf Circumference)

    Calf circumference will be measured at the point of maximum circumference of the right calf using a non-elastic anthropometric tape. Participants will stand upright with their weight evenly distributed between both legs. Three measurements will be obtained without compressing the underlying tissues, and the mean value will be expressed in centimeters (cm).

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  13. Change in Right Rectus Femoris Muscle Thickness

    Right rectus femoris muscle thickness will be assessed using real-time B-mode ultrasound with a linear transducer. Measurements will be obtained at the midpoint between the anterior superior iliac spine and the superior border of the patella. Muscle thickness will be calculated as the perpendicular distance between the superficial and deep aponeuroses, averaged across three ultrasound images. Results will be expressed in centimeters (cm), with higher values indicating greater muscle thickness.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  14. Change in Left Rectus Femoris Muscle Thickness

    Left rectus femoris muscle thickness will be assessed using real-time B-mode ultrasound with a linear transducer. Measurements will be obtained at the midpoint between the anterior superior iliac spine and the superior border of the patella. Muscle thickness will be calculated as the perpendicular distance between the superficial and deep aponeuroses, averaged across three ultrasound images. Results will be expressed in centimeters (cm), with higher values indicating greater muscle thickness.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  15. Change in Right Vastus Lateralis Muscle Thickness

    Right vastus lateralis muscle thickness will be assessed using real-time B-mode ultrasound with a linear transducer. Measurements will be obtained at two-thirds of the distance between the anterior superior iliac spine and the lateral border of the patella. Muscle thickness will be calculated as the perpendicular distance between the superficial and deep aponeuroses, averaged across three ultrasound images. Results will be expressed in centimeters (cm), with higher values indicating greater muscle thickness.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  16. Change in Left Vastus Lateralis Muscle Thickness

    Left vastus lateralis muscle thickness will be assessed using real-time B-mode ultrasound with a linear transducer. Measurements will be obtained at two-thirds of the distance between the anterior superior iliac spine and the lateral border of the patella. Muscle thickness will be calculated as the perpendicular distance between the superficial and deep aponeuroses, averaged across three ultrasound images. Results will be expressed in centimeters (cm), with higher values indicating greater muscle thickness.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  17. Change in Inter-Rectus Distance at 5 cm Above the Umbilicus

    Inter-rectus distance (IRD) will be measured using B-mode ultrasound at 5 cm above the umbilicus. Participants will lie in a supine position with their head supported on a pillow, hips and knees flexed, feet flat on the examination table, and arms resting alongside the body. The distance between the medial borders of the rectus abdominis muscles will be measured and expressed in millimeters (mm), with higher values indicating greater abdominal muscle separation.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  18. Change in Inter-Rectus Distance at 2 cm Above the Umbilicus

    Inter-rectus distance (IRD) will be measured using B-mode ultrasound at 2 cm above the umbilicus. Participants will lie in a supine position with their head supported on a pillow, hips and knees flexed, feet flat on the examination table, and arms resting alongside the body. The distance between the medial borders of the rectus abdominis muscles will be measured and expressed in millimeters (mm), with higher values indicating greater abdominal muscle separation.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  19. Change in Inter-Rectus Distance at 2 cm Below the Umbilicus

    Inter-rectus distance (IRD) will be measured using B-mode ultrasound at 2 cm below the umbilicus. Participants will lie in a supine position with their head supported on a pillow, hips and knees flexed, feet flat on the examination table, and arms resting alongside the body. The distance between the medial borders of the rectus abdominis muscles will be measured and expressed in millimeters (mm), with higher values indicating greater abdominal muscle separation.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  20. Change in Linea Alba Distortion Index at 5 cm Above the Umbilicus

    Linea alba distortion will be assessed using B-mode ultrasound at 5 cm above the umbilicus. Participants will lie supine with their head supported, hips and knees flexed, and feet flat on the examination table. The distortion index will be calculated by dividing the area between the linea alba trajectory and the straight line connecting the medial borders of the rectus abdominis muscles by the inter-rectus distance. Results will be expressed in millimeters (mm), with higher values indicating greater linea alba distortion.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  21. Change in Linea Alba Distortion Index at 2 cm Above the Umbilicus

    Linea alba distortion will be assessed using B-mode ultrasound at 2 cm above the umbilicus. Participants will lie supine with their head supported, hips and knees flexed, and feet flat on the examination table. The distortion index will be calculated by dividing the area between the linea alba trajectory and the straight line connecting the medial borders of the rectus abdominis muscles by the inter-rectus distance. Results will be expressed in millimeters (mm), with higher values indicating greater linea alba distortion.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  22. Change in Linea Alba Distortion Index at 2 cm Below the Umbilicus

    Linea alba distortion will be assessed using B-mode ultrasound at 2 cm below the umbilicus. Participants will lie supine with their head supported, hips and knees flexed, and feet flat on the examination table. The distortion index will be calculated by dividing the area between the linea alba trajectory and the straight line connecting the medial borders of the rectus abdominis muscles by the inter-rectus distance. Results will be expressed in millimeters (mm), with higher values indicating greater linea alba distortion.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  23. Right Perirenal Fat Thickness

    Right perirenal fat thickness will be assessed using B-mode ultrasound. The perirenal fat deposit will be identified using the renal cortex, hepatic pole, and abdominal wall musculature as anatomical landmarks. Thickness will be measured in millimeters (mm), with higher values indicating greater perirenal fat thickness.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  24. Change in Heart Rate Variability (RMSSD)

    Heart rate variability (HRV) will be assessed using a Polar H10 heart rate monitor (Polar Electro Oy, Kempele, Finland) and the Elite HRV application. Participants will perform a five-minute resting measurement on seven consecutive days at each assessment period. HRV will be quantified using the root mean square of successive differences between normal-to-normal heartbeats (RMSSD), expressed in milliseconds (ms). The mean RMSSD across the seven daily measurements will be used as the outcome measure, with higher values generally indicating greater parasympathetic cardiac modulation.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  25. Cardiorespiratory fitness: Indirect method (Six-Minute Walk Distance)

    Functional exercise capacity will be assessed using the Six-Minute Walk Test (6MWT). Participants will be instructed to walk as far as possible during six minutes along a flat, straight corridor. The total distance covered will be recorded in meters (m), with higher values indicating greater functional exercise capacity.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  26. Cardiorespiratory fitness: Direct method (Peak Oxygen Consumption)

    Peak oxygen consumption (VO₂peak) will be assessed during the Six-Minute Walk Test using a portable metabolic analyzer. Participants will wear a face mask connected to the gas analysis system throughout the test. VO₂peak will be expressed in milliliters per kilogram per minute (mL/kg/min), with higher values indicating greater oxygen consumption during exercise.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  27. Five-Repetition Sit-to-Stand Test (5STS)

    Functional capacity will be assessed using the Five-Repetition Sit-to-Stand Test (5STS). Participants will be instructed to stand up and sit down five times as quickly as possible from a standard chair without using their arms. The total time required to complete five repetitions will be recorded in seconds (s), with lower values indicating better functional performance.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  28. 60-Second Sit-to-Stand Test (60STS)

    Functional capacity will be assessed using the 60-Second Sit-to-Stand Test (60STS). Participants will be instructed to complete as many full sit-to-stand repetitions as possible within 60 seconds, without using their arms for assistance. The total number of correctly completed repetitions will be recorded, with higher values indicating better functional performance.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  29. Right-Hand Grip Strength

    Right-hand grip strength will be assessed using a Jamar Smart hand dynamometer. Participants will perform three maximal voluntary contractions with the right hand, with the elbow flexed at 90 degrees and the forearm supported. The highest recorded value will be expressed in kilograms (kg), with higher values indicating greater handgrip strength.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  30. Left-Hand Grip Strength

    Left-hand grip strength will be assessed using a Jamar Smart hand dynamometer. Participants will perform three maximal voluntary contractions with the left hand, with the elbow flexed at 90 degrees and the forearm supported. The highest recorded value will be expressed in kilograms (kg), with higher values indicating greater handgrip strength.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  31. Change in Mean Concentric Velocity at 50% of Baseline Body Weight

    Mean concentric velocity will be assessed during squat exercise using a linear position transducer (SmartCoach, Turin, Italy). Participants will perform three maximal-velocity repetitions with an external load corresponding to 50% of their baseline body weight. Mean concentric velocity will be recorded for each repetition, and the average of the three repetitions will be used as the outcome measure. Results will be expressed in meters per second (m/s), with higher values indicating greater concentric movement velocity.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  32. Change in Mean Concentric Velocity at 75% of Baseline Body Weight

    Mean concentric velocity will be assessed during squat exercise using a linear position transducer (SmartCoach, Turin, Italy). Participants will perform three maximal-velocity repetitions with an external load corresponding to 75% of their baseline body weight. Mean concentric velocity will be recorded for each repetition, and the average of the three repetitions will be used as the outcome measure. Results will be expressed in meters per second (m/s), with higher values indicating greater concentric movement velocity.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  33. Change in Mean Concentric Velocity at 100% of Baseline Body Weight

    Mean concentric velocity will be assessed during squat exercise using a linear position transducer (SmartCoach, Turin, Italy). Participants will perform three maximal-velocity repetitions with an external load corresponding to 100% of their baseline body weight. Mean concentric velocity will be recorded for each repetition, and the average of the three repetitions will be used as the outcome measure. Results will be expressed in meters per second (m/s), with higher values indicating greater concentric movement velocity.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  34. Change in Mean Concentric Power at 50% of Baseline Body Weight

    Mean concentric power will be assessed during squat exercise using a linear position transducer (SmartCoach, Turin, Italy). Participants will perform three maximal-velocity repetitions with an external load corresponding to 50% of their baseline body weight. Mean concentric power will be determined from the force and velocity data obtained during the concentric phase. The average power across the three repetitions will be used as the outcome measure and expressed in watts (W), with higher values indicating greater concentric power production.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  35. Change in Mean Concentric Power at 75% of Baseline Body Weight

    Mean concentric power will be assessed during squat exercise using a linear position transducer (SmartCoach, Turin, Italy). Participants will perform three maximal-velocity repetitions with an external load corresponding to 75% of their baseline body weight. Mean concentric power will be determined from the force and velocity data obtained during the concentric phase. The average power across the three repetitions will be used as the outcome measure and expressed in watts (W), with higher values indicating greater concentric power production.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  36. Change in Mean Concentric Power at 100% of Baseline Body Weight

    Mean concentric power will be assessed during squat exercise using a linear position transducer (SmartCoach, Turin, Italy). Participants will perform three maximal-velocity repetitions with an external load corresponding to 100% of their baseline body weight. Mean concentric power will be determined from the force and velocity data obtained during the concentric phase. The average power across the three repetitions will be used as the outcome measure and expressed in watts (W), with higher values indicating greater concentric power production.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  37. Change in Maximum Dynamic Concentric Force During Squat Exercise

    Maximum dynamic concentric force will be estimated from the force-velocity relationship obtained during squat exercise. Participants will perform three maximal-velocity repetitions at each of three external loads corresponding to 50%, 75%, and 100% of their baseline body weight, with three minutes of rest between sets. Movement velocity will be recorded using a linear position transducer (SmartCoach, Turin, Italy). A single maximum dynamic concentric force value will be derived from the force-velocity profile at each assessment and expressed in newtons (N), with higher values indicating greater estimated force production.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  38. Change in Center of Pressure Sway Area With Eyes Open

    Postural balance will be assessed using a force platform (Hawkin Dynamics) during the Romberg test. Participants will stand upright for 30 seconds with their eyes open. Center of pressure (CoP) sway area will be calculated from the recorded postural sway data and expressed in square millimeters (mm²). Higher values will indicate greater postural sway and reduced postural stability.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  39. Change in Center of Pressure Sway Area With Eyes Closed

    Postural balance will be assessed using a force platform (Hawkin Dynamics) during the Romberg test. Participants will stand upright for 30 seconds with their eyes closed. Center of pressure (CoP) sway area will be calculated from the recorded postural sway data and expressed in square millimeters (mm²). Higher values will indicate greater postural sway and reduced postural stability.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  40. Change in Mean Center of Pressure Velocity With Eyes Open

    Postural balance will be assessed using a force platform (Hawkin Dynamics) during the Romberg test. Participants will stand upright for 30 seconds with their eyes open. Mean center of pressure (CoP) velocity will be calculated as the total CoP displacement divided by the recording duration. Results will be expressed in millimeters per second (mm/s), with higher values indicating greater postural sway velocity.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  41. Change in Mean Center of Pressure Velocity With Eyes Closed

    Postural balance will be assessed using a force platform (Hawkin Dynamics) during the Romberg test. Participants will stand upright for 30 seconds with their eyes closed. Mean center of pressure (CoP) velocity will be calculated as the total CoP displacement divided by the recording duration. Results will be expressed in millimeters per second (mm/s), with higher values indicating greater postural sway velocity.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  42. Perceived exertion

    Perceived exertion will be assessed using the Borg Category-Ratio 10 (CR-10) Rating of Perceived Exertion Scale after each training session. Scores range from 0 (no exertion at all) to 10 (maximal exertion), with higher scores indicating greater perceived exercise intensity. The scores will be recorded throughout the strength training intervention.

    Time frame: After each training session, from the week following baseline assessment (gestational weeks 10-12) until delivery.

  43. Fetal Crown-Rump Length

    Fetal crown-rump length (CRL) will be measured by obstetric ultrasound as the distance between the top of the fetal head (crown) and the bottom of the torso (rump). Measurements will be expressed in millimeters (mm). CRL will be used to assess fetal size and growth during early pregnancy.

    Time frame: Pregnancy: early pregnancy (week 10-12).

  44. Fetal Biparietal Diameter

    Fetal biparietal diameter (BPD) will be assessed by obstetric ultrasound as the transverse diameter of the fetal head between the two parietal bones, using standardized anatomical landmarks. Measurements will be expressed in millimeters (mm). BPD will be used to assess fetal head growth and development.

    Time frame: Pregnancy: mid pregnancy (week 26-28) and late pregnancy (week 34-36).

  45. Fetal Head Circumference

    Fetal head circumference (HC) will be measured by obstetric ultrasound in a standardized axial plane of the fetal head. The circumference will be determined using ultrasound measurement tools and expressed in millimeters (mm). HC will be used to assess fetal head growth and development.

    Time frame: Pregnancy: mid pregnancy (week 26-28) and late pregnancy (week 34-36).

  46. Fetal Femur Length

    Fetal femur length (FL) will be assessed by obstetric ultrasound by measuring the length of the ossified femoral diaphysis, excluding the epiphyses. Measurements will be expressed in millimeters (mm). FL will be used to assess fetal skeletal growth and development.

    Time frame: Pregnancy: mid pregnancy (week 26-28) and late pregnancy (week 34-36).

  47. Fetal Abdominal Circumference

    Fetal abdominal circumference (AC) will be measured by obstetric ultrasound in a standardized transverse plane of the fetal abdomen, at the level of the stomach and portal sinus. Measurements will be expressed in millimeters (mm). AC will be used to assess fetal abdominal growth and identify potential abnormalities in fetal growth.

    Time frame: Pregnancy: mid pregnancy (week 26-28) and late pregnancy (week 34-36).

  48. Mode of Delivery

    Mode of delivery will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. Delivery will be classified as spontaneous vaginal delivery, assisted vaginal delivery, or cesarean section. Results will be reported as the number of participants in each category.

    Time frame: At delivery.

  49. Duration of Labor

    Duration of labor will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. Duration will be calculated as the time elapsed between the documented onset of labor and delivery. Results will be expressed in hours (h), with higher values indicating longer labor duration.

    Time frame: At delivery.

  50. Instrumental Assistance During Delivery

    The use of instrumental assistance during delivery will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. Instrumental assistance will be classified according to the type of instrument used (forceps or vacuum extraction). Results will be reported as the number of participants requiring each type of instrumental assistance.

    Time frame: At delivery.

  51. Newborn Sex

    Newborn sex will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. Results will be reported as the number of newborns in each recorded sex category.

    Time frame: At delivery.

  52. Birth Weight

    Newborn birth weight will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. Birth weight will be expressed in grams (g) and used as an indicator of fetal growth and neonatal status at delivery.

    Time frame: At delivery.

  53. Placental Weight

    Placental weight will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. Placental weight will be expressed in grams (g) and used to assess placental characteristics at delivery.

    Time frame: At delivery.

  54. Apgar Score at 1 Minute

    The Apgar score at 1 minute after birth will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Total scores range from 0 to 10, with higher scores indicating better neonatal condition.

    Time frame: 1 minute after birth.

  55. Apgar Score at 5 Minutes

    The Apgar score at 5 minutes after birth will be reported by participants during the postpartum assessment and, when available, verified using clinical documentation voluntarily provided by participants. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Total scores range from 0 to 10, with higher scores indicating better neonatal condition.

    Time frame: 5 minutes after birth.

  56. Change in Plasma Interleukin-1 (IL-1) Concentration

    Interleukin-1 (IL-1) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in IL-1 concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  57. Change in Plasma Interleukin-6 (IL-6) Concentration

    Interleukin-6 (IL-6) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in IL-6 concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  58. Change in Plasma Interleukin-8 (IL-8) Concentration

    Interleukin-8 (IL-8) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in IL-8 concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  59. Change in Plasma Interleukin-10 (IL-10) Concentration

    Interleukin-10 (IL-10) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in IL-10 concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  60. Change in Plasma Interferon-Gamma (IFN-γ) Concentration

    Interferon-gamma (IFN-γ) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in IFN-γ concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  61. Change in Plasma Tumor Necrosis Factor-Alpha (TNF-α) Concentration

    Tumor necrosis factor-alpha (TNF-α) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in TNF-α concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  62. Change in Plasma C-Reactive Protein (CRP) Concentration

    C-reactive protein (CRP) concentration will be measured in maternal plasma samples obtained from fasting venous blood. Concentrations will be expressed in milligrams per liter (mg/L). Changes in CRP concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  63. Change in Plasma Glucose Concentration

    Fasting glucose concentration will be measured in maternal plasma obtained from venous blood samples collected after an overnight fast. Glucose concentrations will be expressed in milligrams per deciliter (mg/dL). Changes in fasting plasma glucose will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  64. Change in Plasma Insulin Concentration

    Fasting insulin concentration will be measured in maternal plasma obtained from venous blood samples collected after an overnight fast. Insulin concentrations will be expressed in micro-international units per milliliter (µIU/mL). Changes in fasting plasma insulin will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  65. Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Insulin resistance will be estimated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma glucose and insulin concentrations using the formula: fasting insulin (µIU/mL) × fasting glucose (mg/dL) / 405. HOMA-IR is a dimensionless index, with higher values indicating greater insulin resistance. Changes in HOMA-IR will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  66. Change in Homeostatic Model Assessment of Beta-Cell Function (HOMA-B)

    Pancreatic beta-cell function will be estimated using the Homeostatic Model Assessment of Beta-Cell Function (HOMA-B), calculated from fasting plasma glucose and insulin concentrations using the formula: 360 × fasting insulin (µIU/mL) / \[fasting glucose (mg/dL) - 63\]. Results will be expressed as a percentage (%), with higher values indicating greater estimated beta-cell function. Changes in HOMA-B will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  67. Change in Plasma Total Cholesterol Concentration

    Total cholesterol (TC) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in milligrams per deciliter (mg/dL). Changes in total cholesterol concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  68. Change in Plasma Triglyceride Concentration

    Triglyceride (TG) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in milligrams per deciliter (mg/dL). Changes in triglyceride concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  69. Change in Plasma High-Density Lipoprotein Cholesterol (HDL-C) Concentration

    High-density lipoprotein cholesterol (HDL-C) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in milligrams per deciliter (mg/dL). Changes in HDL-C concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  70. Change in Plasma Low-Density Lipoprotein Cholesterol (LDL-C) Concentration

    Low-density lipoprotein cholesterol (LDL-C) concentration will be assessed in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in milligrams per deciliter (mg/dL). Changes in LDL-C concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  71. Change in Plasma Human Chorionic Gonadotropin (hCG) Concentration

    Human chorionic gonadotropin (hCG) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in milli-international units per milliliter (mIU/mL). Changes in hCG concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36).

  72. Change in Plasma Pregnancy-Associated Plasma Protein A (PAPP-A) Concentration

    Pregnancy-associated plasma protein A (PAPP-A) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in milli-international units per liter (mIU/L), subject to the analytical method used. Changes in PAPP-A concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36).

  73. Change in Plasma Placental Growth Factor (PlGF) Concentration

    Placental growth factor (PlGF) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in PlGF concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36).

  74. Change in Plasma Soluble Fms-Like Tyrosine Kinase-1 (sFlt-1) Concentration

    Soluble fms-like tyrosine kinase-1 (sFlt-1) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in sFlt-1 concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36).

  75. Change in Plasma sFlt-1/PlGF Ratio

    The ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) will be calculated from their concentrations measured in maternal plasma samples obtained from fasting venous blood. The sFlt-1/PlGF ratio is dimensionless, with higher values indicating greater angiogenic imbalance. Changes in the ratio will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36).

  76. Change in Plasma Leptin Concentration

    Leptin concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in nanograms per milliliter (ng/mL). Changes in leptin concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  77. Change in Plasma Resistin Concentration

    Resistin concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in nanograms per milliliter (ng/mL). Changes in resistin concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  78. Change in Plasma Irisin Concentration

    Irisin concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in nanograms per milliliter (ng/mL). Changes in irisin concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  79. Change in Plasma Brain-Derived Neurotrophic Factor (BDNF) Concentration

    Brain-derived neurotrophic factor (BDNF) concentration will be measured in maternal plasma obtained from fasting venous blood samples. Concentrations will be expressed in picograms per milliliter (pg/mL). Changes in BDNF concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  80. Change in Blood Hemoglobin (Hb) Concentration

    Hemoglobin (Hb) concentration will be measured in maternal venous whole blood samples using a validated hematological analyzer. Blood samples will be collected under fasting conditions. Hemoglobin concentrations will be expressed in grams per deciliter (g/dL). Changes in hemoglobin concentration will be assessed across the study evaluation points.

    Time frame: Pregnancy: early pregnancy (weeks 10-12), mid-pregnancy (weeks 26-28), and late pregnancy (weeks 34-36). Postpartum: weeks 8-12.

  81. Interleukin-1 (IL-1) Concentration in Colostrum

    Interleukin-1 (IL-1) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  82. Interleukin-6 (IL-6) Concentration in Colostrum

    Interleukin-6 (IL-6) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  83. Interleukin-8 (IL-8) Concentration in Colostrum

    Interleukin-8 (IL-8) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  84. Interleukin-10 (IL-10) Concentration in Colostrum

    Interleukin-10 (IL-10) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  85. Fractalkine (CX3CL1) Concentration in Colostrum

    Fractalkine (CX3CL1) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  86. Tumor Necrosis Factor-Alpha (TNF-α) Concentration in Colostrum

    Tumor necrosis factor-alpha (TNF-α) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  87. Interferon-Gamma (IFN-γ) Concentration in Colostrum

    Interferon-gamma (IFN-γ) concentration will be measured in colostrum samples collected manually after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 24-48 hours postpartum.

  88. Interleukin-1 (IL-1) Concentration in Mature Breast Milk

    Interleukin-1 (IL-1) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

  89. Interleukin-6 (IL-6) Concentration in Mature Breast Milk

    Interleukin-6 (IL-6) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

  90. Interleukin-8 (IL-8) Concentration in Mature Breast Milk

    Interleukin-8 (IL-8) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

  91. Interleukin-10 (IL-10) Concentration in Mature Breast Milk

    Interleukin-10 (IL-10) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

  92. Fractalkine (CX3CL1) Concentration in Mature Breast Milk

    Fractalkine (CX3CL1) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

  93. Tumor Necrosis Factor-Alpha (TNF-α) Concentration in Mature Breast Milk

    Tumor necrosis factor-alpha (TNF-α) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

  94. Interferon-Gamma (IFN-γ) Concentration in Mature Breast Milk

    Interferon-gamma (IFN-γ) concentration will be measured in mature breast milk samples collected manually four weeks after delivery. Samples will be stored at -80 °C until analysis. Concentrations will be expressed in picograms per milliliter (pg/mL).

    Time frame: 4 weeks postpartum.

07

Study locations

1 of 1 sites recruiting
  • Universidad Europea Miguel de Cervantes
    Valladolid, Valladolid 47012, Spain
    Recruiting
    • Alejandro Santos-Lozano, PhD · Contactasantos@uemc.es · 0034983001000
    • Alejandro Santos Lozano, PhD · Principal investigator
    • Paula Redondo-Delgado, MSc · Sub investigator
    • Celia García-Chico, PhD · Sub investigator
    • Susana López-Ortiz, PhD · Sub investigator
    • Kayvan Khoramipour, PhD · Sub investigator
    • Paula Crespo-Escobar, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2026
First posted
Nov 13, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Feb 27, 2028
CompletionEst.
May 31, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934862
Lead sponsor
European University Miguel de Cervantes
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Feb 27, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Alejandro Santos-Lozano, PhD
Contact
asantos@uemc.es
0034983001000
Alejandro Santos-Lozano, PhD
principal investigator · Universidad Europea Miguel de Cervantes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion